Hamada Akinobu

ハマダアキノブ | Hamada Akinobu

Affiliation and department：
Job title： Chief
Other affiliations (1)：

National Cancer Center

Homepage URL (1)： https://www.ncc.go.jp/jp/ri/division/molecular_pharmacology/index.html

Research field (5)： Clinical pharmacy , Clinical pharmacy , Tumor diagnostics and therapeutics , Pharmacology , Pharmaceuticals - chemistry and drug development

Research keywords (5)：創薬開発・薬効試験 , 動物モデル・patient derived xenograft model , 薬物動態・薬力学・薬理遺伝学 , 個別化医療 , 分子イメージング

Research theme for competitive and other funds (8)：

2021 - 2025 Development of a novel cell differentiation cancer therapy
2013 - 2016 Personalized cancer chemotherapy: efficacy and safety based on pharmacokinetics and pharmacogenetics
2009 - 2011 Novel strategy for development of suppressive drugs for kidney disease based on inhibition of metabolic production of uremic toxins
2009 - 2011 Development of personalized medicine for cancer chemotherapy according to a variety of sensitivity and pharmacokinetics
2007 - 2008 Development of an individualized therapy for establishing the optimal dosage by analysis of pharmacological gene

Show all

Papers (187)：

Shigehiro Yagishita, Yuta Yamanaka, Takayasu Kurata, Kageaki Watanabe, Yukio Hosomi, Hidehito Horinouchi, Yuichiro Ohe, Yoshiro Nakahara, Katsuhiko Naoki, Tetsuhiko Asao, et al. Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older. Clinical Pharmacology & Therapeutics. 2024
Shinji Kohsaka, Shigehiro Yagishita, Yukina Shirai, Yusuke Matsuno, Toshihide Ueno, Shinya Kojima, Hiroshi Ikeuchi, Masachika Ikegami, Rina Kitada, Ken-ichi Yoshioka, et al. A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency. npj Precision Oncology. 2024. 8. 1
Masahiro Torasawa, Tatsuya Yoshida, Kouya Shiraishi, Naoko Goto, Toshihide Ueno, Hitoshi Ichikawa, Shigehiro Yagishita, Shinji Kohsaka, Yasushi Goto, Yasushi Yatabe, et al. Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report. JTO clinical and research reports. 2024. 5. 4. 100657-100657
Yuki Katsuya, Tatsuya Yoshida, Atsuo Takashima, Kan Yonemori, Akihiro Ohba, Shu Yazaki, Shigehiro Yagishita, Hiroko Nakahama, Osamu Kobayashi, Masatoshi Yanagida, et al. Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study. International journal of clinical oncology. 2024. 29. 4. 386-397
Kiyoto Tsuchiya, Yoshiharu Hayashi, Shoraku Ryu, Hieu Trung Tran, Misao Takano, Kazuko Tanaka, Daisuke Mizushima, Shinichi Oka, Hiroyuki Gatanaga, Akinobu Hamada. Determination of intracellular tenofovir-diphosphate and emtricitabine-triphosphate concentrations in dried blood spots for pre-exposure prophylaxis adherence. Journal of Infection and Chemotherapy. 2024

ｍore...

MISC (181)：

坂本康成, 肱岡範, 前原耕介, 谷本泉, 丸木雄太, 永塩美邦, 大場彬博, 近藤俊輔, 森実千種, 柳下薫寛, et al. 膵癌EUS-FNA検体からのPatient-derived xenograft(PDX)モデル作製の可能性について. 膵臓. 2019. 34. 3. A248-A248
Makoto Ohno, Mitsuhiro Hayashi, Yuko Matsushita, Yasuji Miyakita, Masamichi Takahashi, Erika Yamazawa, Natsuko Tsushita, Koichi Ichimura, Akinobu Hamada, Yoshitaka Narita. ISOCITRATE DEHYDROGENASE MUTATIONS AND INCREASED TISSUE 2-HYDROXYGLUTARATE CONCENTRATION MIGHT BE RELATED WITH SEIZURE ONSET IN PATIENTS WITH GLIOMAS. NEURO-ONCOLOGY. 2018. 20. 195-195
Mitsuhiro Hayashi, Yukari Tsubata, Hiroaki Aikawa, Kenji Tamura, Yasuhiro Fujiwara, Takeshi Isobe, Akinobu Hamada. Heterogeneous tissue distributions of erlotinib in lung cancer using MALDI mass spectrometry imaging. CANCER SCIENCE. 2018. 109. 902-902
Tadaaki Nishikawa, Mitsuhiro Hayashi, Kosei Hasegawa, Kan Yonemori, Kenji Tamura, Akinobu Hamada. Development of patient derived xenograft models for rare cancers. CANCER SCIENCE. 2018. 109. 172-172
S. Sasada, H. Kurihara, T. Kinoshita, M. Yoshida, N. Honda, T. Shimoi, A. Shimomura, M. Yunokawa, K. Yonemori, C. Shimizu, et al. 64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer. Annals of Oncology. 2017. 28. 8. 2028-2029

ｍore...

Education (2)：

- 1992 Kumamoto University
- 1990 Kumamoto University School of Pharmacy

Professional career (1)：

Doctor of Pharmaceutical Science

Work history (7)：

2022/04 - 現在 National Cancer Center Research institute Fundamental Innovative Oncology Core Center Director
2012/04 - 現在 National Cancer Center
2008 - 2011/03 Kumamoto University
2005/08 - 2007/08 National Cancer Institute/National Institutes of Health Visiting Scientist
2001/04 - 2005/07 Kumamoto University

Show all

Committee career (4)：

日本臨床薬理学会評議員
日本薬物動態学会評議員
日本臨床腫瘍学会評議員
日本癌学会評議員

Awards (5)：

2013/12 - 臨床薬理研究振興財団学術論文賞
2011/11 - 日本薬物動態学会奨励賞慢性骨髄性白血病治療薬イマチニブにおける個別化医療の実践と薬物動態変動要因の解析
2007/05 - ASCO Merit Award Pharmacogenetics of organic anion transporting polypeptides (OATP): An association of a SLCO1B3 polymorphism with the overall survival in white Caucasian patients with androgen independent prostate cancer
2007 - 臨床薬理研究振興財団奨励賞慢性リウマチに対する個別投与設計法の開発
2004/12 - 日本薬学会九州支部奨励賞抗癌薬体内動態情報に基づく個別投与設計法の基盤構築に関する研究

Association Membership(s) (10)：

日本臨床薬理学会 , 日本癌治療学会 , 日本癌学会 , 日本薬学会 , 日本がん分子標的治療学会 , European Society for Medical Oncology , American Society for Clinical Pharmacology & Therapeutics , American Society of Clinical Oncology , American Association for Cancer Research , 日本臨床腫瘍学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page